GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » Market Cap

Alector (Alector) Market Cap : $460.55 Mil (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alector Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alector's share price for the quarter that ended in Dec. 2023 was $7.98. Alector's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 84.88 Mil. Therefore, Alector's market cap for the quarter that ended in Dec. 2023 was $677.34 Mil.

Alector's quarterly market cap increased from Jun. 2023 ($503.82 Mil) to Sep. 2023 ($545.20 Mil) and increased from Sep. 2023 ($545.20 Mil) to Dec. 2023 ($677.34 Mil).

Alector's annual market cap declined from Dec. 2021 ($1,693.02 Mil) to Dec. 2022 ($765.13 Mil) and declined from Dec. 2022 ($765.13 Mil) to Dec. 2023 ($677.34 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alector's Enterprise Value for Today is $-7.26 Mil.


Alector Market Cap Historical Data

The historical data trend for Alector's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Market Cap Chart

Alector Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial 1,189.78 1,200.06 1,693.02 765.13 677.34

Alector Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 765.13 515.95 503.82 545.20 677.34

Competitive Comparison of Alector's Market Cap

For the Biotechnology subindustry, Alector's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alector's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's Market Cap distribution charts can be found below:

* The bar in red indicates where Alector's Market Cap falls into.



Alector Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alector's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.98*84.8797
=$677.34

Alector's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$7.98*84.8797
=$677.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alector  (NAS:ALEC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Alector Market Cap Related Terms

Thank you for viewing the detailed overview of Alector's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Alector (Alector) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Executives
Sara Kenkare-mitra officer: President and Head of R&D C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano officer: Chief Medical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal director, officer: Chief Executive Officer C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso officer: Chief Financial Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire director, 10 percent owner C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond director C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe director C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross director C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr director C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner director C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King officer: Chief Development Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman officer: President and COO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080